Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC003 in Progressive PSMA-positive mCRPC
NCT07567521Phase 2Recruiting
- Sponsor
- C Ray Therapeutics
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of TRC003 in castration-resistant prostate cancer (CRPC) (3 arms), sponsored by C Ray Therapeutics. Primary endpoints: Incidence and severity of Adverse Events and Serious Adverse Events at 60 months and Prostate Specific Antigen response 50% at 12 months. Started May 2026; status: recruiting.
02
Drugs
TRC003
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07567521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07567521.